Company / Cash & Equivalents
UTAH MEDICAL PRODUCTS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$85.8M
FY2025
5-year range
$51.6M / $92.9M
FY2021-FY2025
Trend
+3.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $93M to $86M over the past 2 years.
Based on SEC 10-K filings.
$86M in FY2025 with a 5-year CAGR of +10.9%.
Declined from $93M to $86M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +12.0%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 3.4% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 16.69 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $85.8M | +3.4% |
| FY2024 | $83.0M | -10.7% |
| FY2023 | $92.9M | +52.3% |
| FY2022 | $61.0M | +18.2% |
| FY2021 | $51.6M | +0.9% |
| FY2020 | $51.1M | +28.2% |
| FY2019 | $39.9M | +51.6% |
| FY2018 | $26.3M | +13.0% |
| FY2017 | $23.3M | +20.8% |
| FY2016 | $19.3M | +33.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026